Bolt Biotherapeutics, Inc. - Common Stock (BOLT)

Competitors to Bolt Biotherapeutics, Inc. - Common Stock (BOLT)

Aduro Biotech, Inc.

Aduro Biotech is focused on immunotherapy, particularly leveraging its proprietary platform to develop therapies aimed at activating the immune system against cancer. Both companies, Bolt and Aduro, utilize innovative cancer treatment approaches, but Aduro's advanced pipeline of candidates in the clinical development stage may provide it with an edge in attracting partnerships and investment.

ImmunoGen, Inc.

ImmunoGen specializes in antibody-drug conjugates (ADCs) to treat cancer, focusing on improving the delivery and efficacy of chemotherapy. The companies compete in the cancer therapeutics market, with ImmunoGen's established ADC platform and clinical successes potentially offering it a greater competitive advantage over Bolt's novel therapeutic approaches.

Mirati Therapeutics, Inc.

Mirati is dedicated to genomics-driven medicines, particularly focusing on targeted therapies for cancer. Bolt Biotherapeutics and Mirati are competitors in the oncology field, but Mirati’s substantial investments in research and development, as well as its pipeline of targeted therapies for specific genetic mutations, gives it a stronger competitive footing.

Replimune Group, Inc. 

Replimune is engaged in developing oncolytic virus therapies that aim to selectively infect and destroy cancer cells while sparing normal tissues. Bolt Biotherapeutics and Replimune compete in the oncology space, with both companies capitalizing on novel approaches. However, Replimune's unique oncolytic platform may currently put it at a competitive advantage in terms of attracting investor interest.

TCR2 Therapeutics Inc.

TCR2 Therapeutics harnesses T-cell receptor technology to create therapies designed to personalize treatment for patients with solid tumors and hematologic malignancies. While both TCR2 and Bolt are engaged in the immuno-oncology sector, TCR2's established collaborations with notable pharmaceutical partners and a broader clinical pipeline may enhance its competitive standing in the market.